ClinicalTrials.Veeva

Menu

Prognostic Value of Respiratory System Compliance Under VV-ECMO on 180-day Mortality in COVID-19 ARDS. (COMPLIECMO)

C

Central Hospital, Nancy, France

Status

Completed

Conditions

Mechanical Ventilation Pressure High
Ards
Extracorporeal Membrane Oxygenation

Treatments

Other: No applicable

Study type

Observational

Funder types

Other

Identifiers

NCT05341687
2022PI050

Details and patient eligibility

About

Mortality of patients with COVID-19 associated acute respiratory distress syndrome (CARDS) treated with veno-venous extra-corporal membrane oxygenation (vv-ECMO) is increasing over time since the beginning of the COVID-19 pandemic. The objectives were to retrospectively describe over the first ten days after vv-ECMO implantation, the ventilatory management of CARDS and to assess the impact of static respiratory system compliance (CRS) on the first day of vv-ECMO on 180-day mortality.

Enrollment

122 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients with ARDS secondary to COVID-19 pneumonia requiring ECMO-VV support, hospitalized in the intensive care units of the CHRU of Nancy, Marseille or Bordeaux between 01/03/2020 and 31/12/2021.
  • Age > 18 years old

Exclusion criteria

  • Respiratory parameters not available on ten first day of VV ECMO implantation.
  • Patient refusal to participate in the study

Trial contacts and locations

1

Loading...

Central trial contact

Benjamin PEQUIGNOT, MD; Simon VALENTIN, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems